Drug & intervention
cisplatin
RxCUI 2555
Understanding this RxNorm record
RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.
Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.
Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Cisplatin
Cisplatin is a chemical compound with formula cis-[Pt(NH3)2Cl2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein. Common side effects include bone marrow suppression, hearing problems including severe hearing loss, kidney damage, and vomiting. Other serious side effects include numbness, trouble walking, allergic reactions, electrolyte problems, and heart disease. Use during pregnancy can cause harm to the developing fetus. Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its replication.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10
RECRUITINGA Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.NCT07559929 · 2026-08-19
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24
RECRUITINGLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20
RECRUITINGA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15
RECRUITINGFutibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · 2026-06-24
RECRUITINGBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04
RECRUITINGSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT07662395 · 2026-05-09
RECRUITINGTrial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19
RECRUITINGA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02
RECRUITINGA Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24
RECRUITINGOral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17
RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05
RECRUITINGA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24
RECRUITINGA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08
RECRUITINGA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCNCT07178795 · 2025-09-29
RECRUITINGIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 2025-08-26
RECRUITINGA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03
RECRUITINGA Study of LY4175408 in Participants With Advanced CancerNCT07046923 · 2025-07-28
RECRUITINGProspective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13
RECRUITINGA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITINGA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15
RECRUITINGAdjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World StudyNCT07640048 · 2025-05-04
RECRUITINGA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24
RECRUITINGPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）NCT06927986 · 2025-03-30
RECRUITINGStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06
RECRUITINGStudy of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.NCT06431633 · 2025-02-04
RECRUITINGA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27
RECRUITINGPerioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung CancerNCT06659042 · 2024-11-20
RECRUITINGA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21
RECRUITINGA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07
RECRUITINGA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04
RECRUITINGA Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19
RECRUITINGA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28
RECRUITINGAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerNCT06480864 · 2024-08-09
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06236438 · 2024-04-10
RECRUITINGA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03
RECRUITINGGenomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)NCT06387056 · 2024-04-01
RECRUITINGConditions being studied
Lung Cancer126Non-small Cell Lung Cancer107Breast Cancer40Carcinoma, Non-Small-Cell Lung39Non Small Cell Lung Cancer31Small Cell Lung Cancer22Stage IIIA Non-Small Cell Lung Cancer17Malignant Mesothelioma15Non-squamous Non-small Cell Lung Cancer15NSCLC13Stage IIIB Non-Small Cell Lung Cancer13Metastatic Breast Cancer12Triple Negative Breast Cancer12Head and Neck Cancer10Malignant Pleural Mesothelioma10Non-Small-Cell Lung Carcinoma10Stage IV Non-Small Cell Lung Cancer10Colorectal Cancer9Lung Neoplasms8Recurrent Non-small Cell Lung Cancer8
Research locations
MadridSpain127New YorkNew York, United States125BarcelonaSpain124SeoulSouth Korea115HoustonTexas, United States109TaipeiTaiwan99ChicagoIllinois, United States92BostonMassachusetts, United States91BaltimoreMaryland, United States87Los AngelesCalifornia, United States85St LouisMissouri, United States84ParisFrance78
Leading sponsors
Eli Lilly and Company56Merck Sharp & Dohme LLC49National Cancer Institute (NCI)41AstraZeneca27Hoffmann-La Roche24Bristol-Myers Squibb20M.D. Anderson Cancer Center13Alliance for Clinical Trials in Oncology10European Organisation for Research and Treatment of Cancer - EORTC10Memorial Sloan Kettering Cancer Center10Incyte Corporation9SWOG Cancer Research Network9Dana-Farber Cancer Institute8National Cancer Institute, Naples8Radiation Therapy Oncology Group8
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.